Picture of Dr. Shezad Malik

Texas Onglyza Heart Failure Attorney

Onglyza (Saxagliptin), was developed by the pharmaceutical giants Bristol-Myers Squibb and AstraZeneca for the treatment of Type 2 diabetes. Onglyza and other similar drugs are in a new class of type 2 diabetic treatment agents known as dipeptidyl peptidase-4 (DPP-4) inhibitors.

Kombiglyze XR is a metformin and saxagliptin long-lasting or sustained release version also made by AstraZeneca. Metformin and saxagliptin are oral diabetes medicines that help control blood sugar levels. Metformin works by decreasing glucose (sugar) production in the liver and decreasing absorption of glucose by the intestines. Saxagliptin works by regulating the levels of insulin your body produces after eating.

Injured by Onglyza? Developed Heart Failure?

If you or a loved one has taken Onglyza and suffered heart failure and/or death, you may have an injury claim against AstraZeneca. To learn more about your legal rights, call Dr. Shezad Malik Law Firm at 888-210-9693 for a free case review. Dr. Shezad Malik Law Firm is based in Dallas, Texas and is investigating and accepting Onglyza Heart Failure injuries nationwide.

Onglyza Information

Onglyza received FDA approval in July 2009 and is used to help control high blood sugar in patients with Type 2 diabetes. Kombiglyze XR is a combination pill of Saxagliptin and metformin extended release medications.

AstraZeneca and Bristol-Myers Squibb jointly developed Onglyza and Kombiglyze, and in 2014, AstraZeneca acquired all global rights to make and sell both of the type 2 diabetes drugs. AstraZeneca is a giant global pharmaceutical company with British-Swedish operations and with headquarters in Cambridge, England.

Onglyza Heart Failure side effects

Onglyza has been linked to a 27% increased risk of heart failure, according to a recent clinical trial. The FDA is now investigating the heart risks of Onglyza and other type-2 diabetes dipeptidyl peptidase-4 (DPP-4) inhibitor drugs.

Onglyza mechanism of action

Onglyza is a type-2 diabetes drug that improves blood-sugar control by blocking dipeptidyl peptidase-4 a key enzyme that normally breaks down insulin.

After eating food, there is an increased blood level of glucose, and the small intestine increases production and release of GLP-1 (Glucagon-like peptide-1) and GIP (Gastric inhibitory polypeptide) incretins into the bloodstream. These hormones work to stabilize glucose blood levels.

The enzyme dipeptidyl peptidase-4 begins breaking down the GLP-1 and GIP incretins within minutes of their release.

Onglyza is a DPP-4 inhibitor and Onglyza blocks DPP-4 enzymes for a 24-hour period, prolonging the body’s own action of naturally secreted incretins GLP-1 and GIP.

GLP-1 signals to the pancreas to decrease glucose release by pancreatic alpha cells, which reduces hepatic (liver) glucose productions.

GLP-1 and GIP increase insulin release by signaling the pancreatic beta cells, which increase uptake of glucose by the muscle, fat, and peripheral tissues.

By blocking DPP-4, Onglyza helps to reduce fasting plasma glucose, and post-meal glucose in a glucose-dependent manner, which helps to reduce blood glucose levels and A1C.

FDA Safety Warning for Onglyza and Heart Failure

The New England Journal of Medicine has published results of a clinical trial (SAVOR-TIMI 53) linking Onglyza to a 27% increased risk of hospitalization for heart failure.

Researchers followed 16,492 patients with type-2 diabetes who had a history of heart disease or other risk factors. They were put into 2 groups, one taking Onglyza and the other a placebo and followed for a median of 2.1 years. At the end of the study, 3.5% of patients on Onglyza were hospitalized for heart failure, versus 2.8% of those on a placebo.

The FDA added Heart Failure warnings for Onglyza in April 2016. The FDA also has urged patients and healthcare professionals to report Onglyza heart failure side effects to the FDA MedWatch program.

Onglyza (saxagliptin, specifically) also has been linked to an increased risk of pancreatitis and pancreatic cancer.

Onglyza Heart Failure Lawsuit

If you or a loved one has taken Onglyza or Kombiglyze and suffered heart failure and/or death, you may have a personal injury, product liability case for compensation against AstraZeneca. To learn more about your legal rights, call Dr. Shezad Malik Law Firm at 888-210-9693 for a free case review. Dr. Shezad Malik Law Firm is based in Dallas, Texas and is investigating and accepting Onglyza Heart Failure Injury cases nationwide.

Contact Us For a Free Consultation
214-390-3189888-210-9693